• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康志愿者中14C-替考拉宁的药代动力学

Pharmacokinetics of 14C-teicoplanin in healthy volunteers.

作者信息

Buniva G, Del Favero A, Bernareggi A, Patoia L, Palumbo R

机构信息

Institute of First Internal Medicine, University of Perugia, Italy.

出版信息

J Antimicrob Chemother. 1988 Jan;21 Suppl A:23-8. doi: 10.1093/jac/21.suppl_a.23.

DOI:10.1093/jac/21.suppl_a.23
PMID:2965128
Abstract

Five healthy male volunteers received over 60 sec a single intravenous injection of 400 mg of teicoplanin labelled with 41 microCi of 14C. Plasma and urine total radioactivity was measured up to 10 and 16 days, respectively. Teicoplanin was assayed in plasma and urine also by a microbiological method, with similar results. Pharmacokinetic parameters were estimated by model-independent analysis and the following mean values were obtained: elimination half-life 77 h; total body clearance 9.8 ml/h/kg; renal clearance 7.81 ml/h/kg; volume of distribution at steady-state 0.759 l/kg. Similar estimates were obtained by a compartmental analysis. A total of 80% of the administered dose was recovered in urine in 16 days; 2.7% of the dose was recovered in faeces collected for eight days after administration. The mean total recovery of the drug was 83 +/- 0.6%. The plasma and urine concentrations of teicoplanin observed after a single 400 mg iv dose exceeded the MIC for most pathogens for at least one day, and this suggests that a daily dosage regimen would be satisfactory for patients with normal renal function.

摘要

5名健康男性志愿者在60多秒内接受了单次静脉注射400毫克标记有41微居里¹⁴C的替考拉宁。分别在长达10天和16天内测定血浆和尿液中的总放射性。还通过微生物学方法测定血浆和尿液中的替考拉宁,结果相似。通过非模型分析估算药代动力学参数,得出以下平均值:消除半衰期77小时;全身清除率9.8毫升/小时/千克;肾清除率7.81毫升/小时/千克;稳态分布容积0.759升/千克。通过房室分析也得到了类似的估算值。16天内尿液中回收了80%的给药剂量;给药后8天收集的粪便中回收了2.7%的剂量。药物的平均总回收率为83±0.6%。单次静脉注射400毫克剂量后观察到的替考拉宁血浆和尿液浓度超过了大多数病原体的最低抑菌浓度至少一天,这表明对于肾功能正常的患者,每日给药方案是令人满意的。

相似文献

1
Pharmacokinetics of 14C-teicoplanin in healthy volunteers.健康志愿者中14C-替考拉宁的药代动力学
J Antimicrob Chemother. 1988 Jan;21 Suppl A:23-8. doi: 10.1093/jac/21.suppl_a.23.
2
Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers.
Biopharm Drug Dispos. 1992 Apr;13(3):213-20. doi: 10.1002/bdd.2510130307.
3
Pharmacokinetics of teicoplanin in subjects with varying degrees of renal function.
J Antimicrob Chemother. 1989 Jun;23(6):869-76. doi: 10.1093/jac/23.6.869.
4
Pharmacokinetics of teicoplanin in the elderly.
J Antimicrob Chemother. 1988 Jan;21 Suppl A:39-45. doi: 10.1093/jac/21.suppl_a.39.
5
Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers.在健康男性志愿者身上,以每千克体重3毫克、12毫克和30毫克的剂量多次静脉注射替考拉宁后的药代动力学。
Antimicrob Agents Chemother. 1992 Jan;36(1):115-20. doi: 10.1128/AAC.36.1.115.
6
Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses.替考拉宁单次递增剂量给药后在健康志愿者体内的药代动力学及耐受性研究
Antimicrob Agents Chemother. 1991 Dec;35(12):2551-7. doi: 10.1128/AAC.35.12.2551.
7
Pharmacokinetics of teicoplanin in pediatric patients.替考拉宁在儿科患者中的药代动力学。
Antimicrob Agents Chemother. 1988 Aug;32(8):1223-6. doi: 10.1128/AAC.32.8.1223.
8
Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans.
J Pharm Sci. 1991 Jun;80(6):605-7. doi: 10.1002/jps.2600800621.
9
Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia.糖肽在胫骨感染性假关节患者中的骨穿透情况。
Clin Pharmacokinet. 2008;47(12):793-805. doi: 10.2165/0003088-200847120-00004.
10
The pharmacokinetics of teicoplanin in varying degrees of renal function.
Clin Pharmacol Ther. 1990 May;47(5):655-61. doi: 10.1038/clpt.1990.87.

引用本文的文献

1
Pharmacokinetics and Target Attainment of Teicoplanin: A Systematic Review.替考拉宁的药代动力学与达标情况:一项系统评价
Clin Pharmacokinet. 2025 Apr;64(4):467-509. doi: 10.1007/s40262-025-01483-7. Epub 2025 Mar 10.
2
Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition.替考拉宁生理基于药代动力学模型为其在体内的分布对血清白蛋白和肾功能的理论影响提供了定量评估。
Eur J Clin Pharmacol. 2021 Aug;77(8):1157-1168. doi: 10.1007/s00228-021-03098-w. Epub 2021 Feb 1.
3
A risk-benefit assessment of teicoplanin in the treatment of infections.
替考拉宁治疗感染的风险效益评估。
Drug Saf. 1995 Nov;13(5):317-28. doi: 10.2165/00002018-199513050-00005.
4
Efficacy and pharmacokinetics of teicoplanin in hemodialysis patients.替考拉宁在血液透析患者中的疗效及药代动力学
Infection. 1993 Jan-Feb;21(1):71-4. doi: 10.1007/BF01739321.
5
Teicoplanin metabolism in rats.替考拉宁在大鼠体内的代谢
Antimicrob Agents Chemother. 1989 Oct;33(10):1791-4. doi: 10.1128/AAC.33.10.1791.
6
Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses.健康志愿者静脉注射负荷剂量和维持剂量后替考拉宁的药代动力学。
Antimicrob Agents Chemother. 1990 Nov;34(11):2114-7. doi: 10.1128/AAC.34.11.2114.
7
Pharmacokinetics of individual components of teicoplanin in man.替考拉宁各组分在人体中的药代动力学。
J Pharmacokinet Biopharm. 1990 Dec;18(6):525-43. doi: 10.1007/BF01073937.
8
Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.替考拉宁:抗菌活性、药代动力学特性及治疗潜力综述
Drugs. 1990 Sep;40(3):449-86. doi: 10.2165/00003495-199040030-00007.
9
Clinical pharmacokinetics of teicoplanin.替考拉宁的临床药代动力学
Clin Pharmacokinet. 1990 Mar;18(3):184-209. doi: 10.2165/00003088-199018030-00002.
10
Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses.替考拉宁单次递增剂量给药后在健康志愿者体内的药代动力学及耐受性研究
Antimicrob Agents Chemother. 1991 Dec;35(12):2551-7. doi: 10.1128/AAC.35.12.2551.